First line (1L) durvalumab in patients with PD-L1 positive, advanced non-small cell lung cancer (NSCLC) with a performance status of 2 (PS2). Primary analysis of the multicenter, single-arm phase II trial SAKK 19/17

被引：0
|
作者：
Mark, M. [1 ]
Froesch, P. [2 ]
Gysel, K. [3 ]
Rothschild, S. [4 ]
Addeo, A. [5 ]
Ackermann, C. [6 ]
Chiquet, S. [3 ]
Schneider, M. [3 ]
Ribi, K. [3 ]
Fischer, A. [1 ]
Bastian, S. [1 ]
von Moos, R. [7 ]
Joerger, M. [8 ]
Frueh, M. [8 ]
机构：
[1] Cantonal Hosp Graubunden, Oncol Hematol, Chur, Switzerland
[2] Cantonal Hosp Bellinzona, Oncol, Bellinzona, Switzerland
[3] SAKK, Coordinating Ctr, Bern, Switzerland
[4] Cantonal Hosp Baden, Oncol Hematol, Baden, Switzerland
[5] Geneva Univ Hosp, Oncol, Geneva, Switzerland
[6] Hosp Thun, Oncol Hematol, Thun, Switzerland
[7] Cantonal Hosp Graubunden, Tumor & Res Ctr, Chur, Switzerland
[8] Cantonal Hosp St Gallen, Oncol Hematol, St Gallen, Switzerland
来源：
SWISS MEDICAL WEEKLY | 2023年 / 153卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
218
引用
收藏
页码：7S / 7S
页数：1
相关论文
共 50 条
  • [21] Randomised phase II trial of 4 dose levels of single agent docetaxel in performance status (PS) 2 patients with advanced non-small cell lung cancer (NSCLC): DOC PS2 trial. Manchester lung cancer group
    Califano, Raffaele
    Griffiths, Richard
    Lorigan, Paul
    Ashcroft, Linda
    Taylor, Paul
    Burt, Paul
    Lee, Lip
    Chittalia, Abbas
    Harris, Margaret
    Faivre-Finn, Corinne
    Thatcher, Nick
    Blackhall, Fiona
    LUNG CANCER, 2011, 73 (03) : 338 - 344
  • [22] The feasibility of weekly paclitaxel in improving performance status(PS) of advanced non-small cell lung cancer (NSCLC) patients with poor performance status: A single-arm phase two trial.
    Pathak, Neha
    Garg, Rakesh
    Mohan, Anant
    Kumar, Akash
    Khurana, Sachin
    Pushpam, Deepam
    Pathy, Sushmita
    Yadav, Mukesh
    Prasad, Chandra Prakash
    Malik, Prabhat Singh
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [23] REAL WORLD OUTCOMES OF FIRST LINE PEMBROLIZUMAB MONOTHERAPY FOR ADVANCED PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER
    Chu, R.
    Vegas, A.
    Gorry, C.
    Power, D.
    VALUE IN HEALTH, 2022, 25 (01) : S253 - S253
  • [24] Outcomes of anti-PD-(L)1 therapy with or without chemotherapy (chemo) for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score ≥ 50%: FDA pooled analysis.
    Akinboro, Oladimeji
    Vallejo, Jonathon Joseph
    Nakajima, Erica C.
    Ren, Yi
    Mishra-Kalyani, Pallavi Shruti
    Larkins, Erin A.
    Vellanki, Paz J.
    Drezner, Nicole Lauren
    Mathieu, Luckson Noe
    Donoghue, Martha Boeri
    Tang, Shenghui
    Pazdur, Richard
    Beaver, Julia A.
    Singh, Harpreet
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] VACTOSERTIB AND DURVALUMAB AS SECOND OR LATER LINE TREATMENT FOR PD-L1 POSITIVE NON-SMALL CELL LUNG CANCER: INTERIM RESULT
    Cho, Byoung Chul
    Lee, Ki Hyeong
    Han, Ji-Youn
    Shim, Byoung Yong
    Kim, Hye Ryun
    Pyo, Kyoung-Ho
    Kim, Jae-Hwan
    Xin, Chung-Feng
    Lee, Jin Kyung
    Ryu, Jiyeon
    Oh, Bitna
    Hwang, Sunjin
    Hahm, Ki Baik
    Kim, Seong-Jin
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A222 - A222
  • [26] Clinical benefit of PD-1/PD-L1 inhibitors for poor performance status patients with advanced non-small cell lung cancer
    Koyama, Junji
    Morise, Masahiro
    Tanaka, Ichidai
    Hori, Sho
    Matsuzawa, Reiko
    Ozone, Sachiko
    Matsushita, Akihiro
    Matsuo, Masaki
    Asano, Shuichi
    Tanaka, Taro
    Shima, Koichiro
    Kimura, Tomoki
    Sakamoto, Koji
    Kondoh, Yasuhiro
    Hashimoto, Naozumi
    JOURNAL OF CHEMOTHERAPY, 2025,
  • [27] TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
    Cao, Xiaobo
    Zhao, Yang
    Wang, Jing
    Dai, Bingbing
    Gentile, Emanuela
    Lin, Jing
    Pu, Xingxiang
    Ji, Lin
    Wu, Shuhong
    Meraz, Ismail
    Majidi, Mourad
    Roth, Jack A.
    ONCOTARGET, 2017, 8 (64) : 107621 - 107629
  • [28] Budget impact (BI) analysis of cemiplimab for first-line (1L) advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50% in the United States.
    Kuznik, Andreas
    Smare, Caitlin
    Chen, Chieh-I
    Venkatachalam, Meena
    Keeping, Sam
    Atsou, Kokuvi
    Xu, Yingxin
    Wilson, Florence
    Guyot, Patricia
    Chan, Keith
    Glowienka, Emily
    Konidaris, Gerasimos
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [29] Randomized open-label study of M7824 versus pembrolizumab as first-line (1L) treatment in patients with PD-L1 expressing advanced non-small cell lung cancer (NSCLC).
    Ahn, Myung-Ju
    Barlesi, Fabrice
    Felip, Enriqueta
    Garon, Edward B.
    Martin, Claudio Marcelo
    Mok, Tony S. K.
    Vokes, Everett E.
    Ojalvo, Laureen S.
    Koenig, Andre
    Dussault, Isabelle
    Paz-Ares, Luis G.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [30] PD-L1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer in PD-L1 positive patients: A safety data network meta-analysis
    Garcia Campelo, M. R.
    Arriola Aperribay, E.
    Campos Balea, B.
    Lopez-Brea, M.
    Fuentes Pradera, J.
    de Castro Carpeno, J.
    Aguado, C.
    Perez Parente, D.
    de Oro-Pulido, F.
    Rodriguez Abreu, D.
    ANNALS OF ONCOLOGY, 2021, 32 : S1413 - S1414
12345